RE:RE:RE:RE:RE:RE:More coverage in China I do also hope that will be the case, the investors here on the board seem to be watching everything which can influence the valuation from company's execution, analysts' coverage, agencies' recent decisions, political influence(drug pricing) and other players in the industry etc, the fact is analysts have to be analysts, their job is to do decent analysis of all company's assets, company has to be company, its job is to deliver and make sure those progresses are understood by the market and investors have to be investors their job is to evaluate the analysts reports and the company do their DD and make a thesis for their investment. All have a job to do. The important part to me is the company by clear and frequent communications with both analysts and investors make sure everyone can do their job. The PDC technology is innovative and potentially "the next big thing" if and when more drugs get approved, now THTX has a job to do during this process.
SPCEO1 wrote: It will really help TH's stock price if PDC become the next "big thing" in drug research and if their phasw 1a results are impressive. TH could be seen as the leader in this new area if that is how it plays out and that would defintely help the share price a lot. Let's hope everything falls nicely into place in the months ahead.
scarlet1967 wrote: It seems like there are more coverage of the targeted drug delivery now, all these frequent articles are new, never came across them before!
Recently, another biomedical company called Theratechnologies also announced the research progress of two PDCs in its R&D pipeline. Up to now, two PDC products have been approved worldwide, and a number of PDC products have entered the clinical stage. At present, this field has attracted international pharmaceutical giants including Novartis, AstraZeneca, Roche, etc. to deploy one after another. Domestic innovative drug companies such as Sheng Nuoji Pharmaceutical and Mainstream Biology have also begun to conduct PDC research and development.
Based on its versatility and advantages, PDC is a research field with broad development prospects. As more innovative biomedical companies join, PDC drugs are expected to achieve rapid development.
https://m.jrj.com.cn/madapter/stock/2021/09/07085333396635.shtml